Bruce E. Johnson

87.4k total citations · 15 hit papers
420 papers, 50.6k citations indexed

About

Bruce E. Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bruce E. Johnson has authored 420 papers receiving a total of 50.6k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Pulmonary and Respiratory Medicine, 255 papers in Oncology and 112 papers in Molecular Biology. Recurrent topics in Bruce E. Johnson's work include Lung Cancer Treatments and Mutations (239 papers), Lung Cancer Research Studies (129 papers) and Lung Cancer Diagnosis and Treatment (78 papers). Bruce E. Johnson is often cited by papers focused on Lung Cancer Treatments and Mutations (239 papers), Lung Cancer Research Studies (129 papers) and Lung Cancer Diagnosis and Treatment (78 papers). Bruce E. Johnson collaborates with scholars based in United States, United Kingdom and France. Bruce E. Johnson's co-authors include Pasi A. Jänne, Matthew Meyerson, Neal I. Lindeman, Michael J. Eck, Titus J. Boggon, David M. Jackman, Sean Tracy, Jeffrey A. Engelman, Jeffrey C. Lee and Katsuhiko Naoki and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Bruce E. Johnson

402 papers receiving 49.3k citations

Hit Papers

EGFR Mutations in Lung Ca... 1994 2026 2004 2015 2004 2007 2005 1994 2001 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
    2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →
  2. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
    2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
  3. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
    2005 3.2k citations Titus J. Boggon, Pasi A. Jänne et al. profile →
  4. A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
    1994 2.3k citations Bruce E. Johnson et al. Science profile →
  5. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
    2001 2.0k citations Eugene J. Mark, Bruce E. Johnson et al. profile →
  6. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
    2005 1.2k citations Roy S. Herbst, Bruce E. Johnson et al. Journal of Clinical Oncology profile →
  7. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
    2005 1.2k citations Bruce E. Johnson, Roy S. Herbst et al. Journal of Clinical Oncology profile →
  8. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
    1999 1.2k citations Bruce E. Johnson et al. profile →
  9. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
    2017 948 citations Bruce E. Johnson et al. profile →
  10. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
    2008 661 citations Lecia V. Sequist, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
  11. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    2009 644 citations David M. Jackman, Jeffrey A. Engelman et al. Journal of Clinical Oncology profile →
  12. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
    2016 612 citations Bruce E. Johnson et al. profile →
  13. Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
    2009 526 citations Scott J. Rodig, Mari Mino–Kenudson et al. Clinical Cancer Research profile →
  14. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
    2005 499 citations Bruce E. Johnson et al. Clinical Cancer Research profile →
  15. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
    2016 334 citations Bruce E. Johnson et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Bruce E. Johnson 29.7k 29.3k 20.8k 9.7k 4.1k 420 50.6k
Tony Mok 35.7k 1.2× 39.6k 1.4× 15.8k 0.8× 12.5k 1.3× 3.9k 0.9× 683 56.7k
Frances A. Shepherd 31.4k 1.1× 32.9k 1.1× 12.2k 0.6× 7.3k 0.8× 4.6k 1.1× 671 49.5k
Vincent A. Miller 29.8k 1.0× 30.6k 1.0× 16.1k 0.8× 10.5k 1.1× 2.0k 0.5× 478 45.7k
Pasi A. Jänne 35.9k 1.2× 40.7k 1.4× 25.7k 1.2× 13.6k 1.4× 2.0k 0.5× 653 61.5k
Marc Ladanyi 24.3k 0.8× 35.6k 1.2× 22.3k 1.1× 13.2k 1.4× 2.9k 0.7× 617 57.2k
Mark G. Kris 36.3k 1.2× 38.5k 1.3× 16.7k 0.8× 9.4k 1.0× 2.4k 0.6× 661 62.4k
Matthew Meyerson 22.7k 0.8× 19.9k 0.7× 34.3k 1.7× 13.8k 1.4× 2.7k 0.7× 287 58.9k
Roy S. Herbst 31.9k 1.1× 26.5k 0.9× 17.0k 0.8× 9.2k 1.0× 1.7k 0.4× 583 50.9k
Jaap Verweij 28.2k 0.9× 22.3k 0.8× 13.7k 0.7× 5.6k 0.6× 3.1k 0.8× 621 55.4k
Yi‐Long Wu 28.8k 1.0× 35.1k 1.2× 12.7k 0.6× 10.1k 1.0× 1.4k 0.4× 1.1k 46.0k

Countries citing papers authored by Bruce E. Johnson

Since Specialization
Citations

This map shows the geographic impact of Bruce E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce E. Johnson more than expected).

Fields of papers citing papers by Bruce E. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce E. Johnson. The network helps show where Bruce E. Johnson may publish in the future.

Co-authorship network of co-authors of Bruce E. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce E. Johnson. A scholar is included among the top collaborators of Bruce E. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce E. Johnson. Bruce E. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirsch, Fred R., Paul A. Bunn, Peter Ujházy, et al.. (2024). Calls to action on lung cancer management and research. The Oncologist. 29(12). e1634–e1645. 1 indexed citations
2.
Ahn, M-J., Ibiayi Dagogo‐Jack, Francesco Gelsomino, et al.. (2024). LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1246–S1247. 2 indexed citations
3.
Lederman, Ruth, et al.. (2024). Young lung cancer: Psychosocial needs assessment.. Journal of Clinical Oncology. 42(16_suppl). 12104–12104. 1 indexed citations
4.
Alessi, Joao V., Adam Price, Allison L. Richards, et al.. (2023). Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(11). e007618–e007618. 5 indexed citations
5.
Gomy, Israel, Alexander Gusev, Bruce E. Johnson, et al.. (2021). Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precision Oncology. 5(5). 1749–1757. 9 indexed citations
6.
Wang, Xinan, Biagio Ricciuti, Tom Nguyen, et al.. (2021). Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer. Cancer Research. 81(9). 2566–2573. 85 indexed citations
7.
Johnson, Bruce E.. (2019). Visual Studio Code. 1 indexed citations
8.
Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations
9.
Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations
10.
Nilsson, Monique B., Uma Giri, Jayanthi Gudikote, et al.. (2015). KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research. 22(8). 1940–1950. 10 indexed citations
11.
Cardarella, Stephanie, Atsuko Ogino, Mizuki Nishino, et al.. (2013). Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(16). 4532–4540. 274 indexed citations
12.
Cho, Jeonghee, Liang Chen, Naveen F. Sangji, et al.. (2013). Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. Cancer Research. 73(22). 6770–6779. 86 indexed citations
13.
Mino–Kenudson, Mari, Lucian R. Chirieac, Jason L. Hornick, et al.. (2010). A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry. Clinical Cancer Research. 16(5). 1561–1571. 327 indexed citations
14.
Rodig, Scott J., Mari Mino–Kenudson, Sanja Đačić, et al.. (2009). Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population. Clinical Cancer Research. 15(16). 5216–5223. 526 indexed citations breakdown →
15.
Hanrahan, Emer O., Anderson J. Ryan, Helen Mann, et al.. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer. Clinical Cancer Research. 15(10). 3600–3609. 69 indexed citations
16.
Yonesaka, Kimio, Kreshnik Zejnullahu, Neal I. Lindeman, et al.. (2008). Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research. 14(21). 6963–6973. 96 indexed citations
17.
Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 316(5827). 1039–1043. 3570 indexed citations breakdown →
18.
Ji, Hongbin, Zhenxiong Wang, Samanthi A. Perera, et al.. (2007). Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. Cancer Research. 67(10). 4933–4939. 137 indexed citations
19.
Jackman, David M., Beow Y. Yeap, Lecia V. Sequist, et al.. (2006). Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research. 12(13). 3908–3914. 491 indexed citations
20.
Paez, J. Guillermo, Pasi A. Jänne, Jeffrey C. Lee, et al.. (2004). EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science. 304(5676). 1497–1500. 7539 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tony Mok Breakdown of academic impact, for papers by Frances A. Shepherd Breakdown of academic impact, for papers by Vincent A. Miller Breakdown of academic impact, for papers by Pasi A. Jänne Breakdown of academic impact, for papers by Marc Ladanyi Breakdown of academic impact, for papers by Mark G. Kris Breakdown of academic impact, for papers by Matthew Meyerson Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Yi‐Long Wu
Rankless by CCL
2026